Double-Blind Placebo-Controlled Trial of Elfornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III
The purpose of this study is to determine if eflornithine and sulindac, taken alone or in combination, can decrease the risk of high-risk adenomas or second primary colorectal cancers (second primary colorectal cancer means a new colorectal cancer developing within the colorectum). Colorectal adenomas are tiny growths in the colon that may eventually lead to cancer. Participants in this study have a history of Stage 0, I, II, or III colon cancer that has been treated with surgery alone or in combination with chemotherapy.
Back to Clinical Trials list